SEC Company Response from PEREGRINE PHARMACEUTICALS INC (CDMO) (CIK 0000704562) — Sep 20, 2005
PEREGRINE PHARMACEUTICALS INC (CDMO) (CIK 0000704562)
Date: Sept. 20, 2005 · CIK: 0000704562 · Accession: 0001019687-05-002646
AI Filing Summary & Sentiment
File numbers found in text: 333-128322
Referenced dates: September 19, 2005
Letter
Division of Corporate Finance Securities and Exchange Commission RE: Peregrine Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-128322
Dear Mr. Riedler:
Enclosed please find three (3) copies of the Pre-Effective Amendment No. 1 (the “Amendment”) to the Company’s Registration Statement on Form S-3 filed September 14, 2005, File Number 333-128322 (the “Registration Statement”). By letter dated September 19, 2005, the Securities and Exchange Commission (the “Commission”) noted the following comment:
1. We note the filing does not include the signature of your principal accounting officer and principal financial officer. Please include these signatures in your amended Form S-3. If Paul J. Lytle serves in these capacities, his signature should be captioned as such in your amended filing. See Instructions 1 and 2 to the Signatures section of Form S-3.
The Company notes the Commission’s comment and has revised the signature page to properly identify Mr. Lytle as the Company’s principal accounting officer and principal financial officer.
Mr. Jeffrey P. Riedler
September 20, 2005
Page
If you have any questions, please do not hesitate to give me a call at (714) 427-7402.
Very
truly yours,
Snell
& Wilmer
Show Raw Text
CORRESP
1
filename1.htm
Peregrine Correspondence
Snell
& Wilmer LLP
600 Anton Bouleveard
Suite 1400
Costa Mesa,
California 92626-7689
TELEPHONE: (714) 427-7000
FACSIMILE: (714)
427-7799
Mark
R. Ziebell
714.427.7402
mziebell@swlaw.com
September
20, 2005
Via
Federal Express
Division
of Corporate Finance
Securities
and Exchange Commission
450
Fifth
Street, N.W.
Washington,
D.C. 20549
Mail
Stop
6010
Attn.:
Jeffrey P. Riedler, Assistant Director
RE:
Peregrine
Pharmaceuticals, Inc. (the “Company”)
Registration
Statement on Form S-3
File
No. 333-128322
Dear
Mr.
Riedler:
Enclosed
please find three (3) copies of the Pre-Effective Amendment No. 1 (the
“Amendment”) to the Company’s Registration Statement on Form S-3 filed September
14, 2005, File Number 333-128322 (the “Registration Statement”). By letter dated
September 19, 2005, the Securities and Exchange Commission (the “Commission”)
noted the following comment:
1. We
note the filing does not include the signature of your principal accounting
officer and principal financial officer. Please include these signatures in
your
amended Form S-3. If Paul J. Lytle serves in these capacities, his signature
should be captioned as such in your amended filing. See Instructions 1 and
2 to
the Signatures section of Form S-3.
The
Company notes the Commission’s comment and has revised the signature page to
properly identify Mr. Lytle as the Company’s principal accounting officer and
principal financial officer.
Mr.
Jeffrey P. Riedler
September
20, 2005
Page
2
If
you
have any questions, please do not hesitate to give me a call at (714)
427-7402.
Very
truly yours,
Snell
& Wilmer
/s/
MARK R. ZIEBELL
Mark
R. Ziebell
MRZ:rp